These data move us closer to our final goal of improving both the duration of response and safety for patients with moderate to severe chronic plaque psoriasis. We are looking forward to the results of the Phase III clinical trials which will be available mid-year. Earlier Phase II trials yielded promising results including remission in some patients without rebound. Psoriasis is a T-cell mediated inflammatory disorder of the skin that can cause considerable discomfort. It is a disease for which there is no cure and affects people of all ages.
Psoriasis affects approximately two percent of the populations of European and North America.
The rash of psoriasis consists of red, scaly areas that commonly occur on the scalp, elbows and knees. In moderate and severe cases, the involved areas can be extensive and cover a substantial percentage of a patient's body. In addition, limited disease can be considered severe if occurring on critical areas such as the palms or soles. Although individuals with mild psoriasis can often control their disease with topical agents, more than one million patients worldwide require ultraviolet or systemic immunosuppressive therapy. Unfortunately, the inconvenience and risks of ultraviolet radiation and the toxicities of many therapies limit their long-term use.